Navigation Links
Neuland Labs Launches Expanded Peptide Manufacturing Capabilities at 22nd American Peptide Symposium
Date:6/22/2011

HYDERABAD, India, June 22, 2011 /PRNewswire/ -- Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced it will unveil its expanded capabilities for synthetic peptide manufacture at the 22nd American Peptide Symposium to be held in San Diego June 25-30, 2011.

"It is fitting that we formally launch our new commercial-scale peptide production service at this important gathering of leading peptide experts from around the world," said M.K. "Mike" Anwer, Ph.D., vice president of research & development at Neuland Labs.  "Neuland's extensive experience in producing a variety of synthetic peptides parallels their increasing use as therapeutics and diagnostics, in antibody production and as research tools.  Our expanded service provides rapid access to commercial quantities of affordable, high quality peptides from a company with a 27-year track record of consistently achieving the highest regulatory standards in global pharmaceutical production."

Neuland Labs offers customers peptide production using standard sequential chemical peptide syntheses and segment condensation strategies.  The company employs solid phase peptide synthesis procedures, as well as solution phase methods for shorter length peptides, and segment condensation and ligation techniques for very long peptides.  Neuland researchers have also developed special methods to economically produce large quantities of high value peptide building blocks such as pseudoproline dipeptides.

Dr. Anwer added, "Our researchers have developed expertise in producing peptides of varying lengths and complexity.  We are especially proud of our success in applying advanced methods for handling the aggregation and purification issues inherent in manufacturing long and complex peptides.  Our diverse peptide customers also benefit from our value-added consultative services in analytical R&D and drug design, process development, optimization, validation, scale-up and the entire regulatory review and approval process.  We work with companies of all sizes and are interested in exploring opportunities for collaborative efforts with a variety of potential partners."

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing.  Neuland scientists have developed more than 300 processes from bench scale to commercial production and have filed more than 400 drug master files worldwide.  The company has a longstanding record of regulatory excellence, as demonstrated by seven successful FDA inspections since 1997, with the most recent completely free of any Form 483 investigational observations.  Neuland's cGMP certifications also include the TGA, EDQM, German Health Authority, ISO 14001, ISO 27001 and OHSAS 18001.  

"Our new commercial-scale peptide manufacturing service reflects our ongoing strategy to leverage Neuland Labs' innovative scientists, world-class manufacturing expertise, established infrastructure and reputation for quality to expand into new market segments.  At a time when efficiency is critical to business success, we expect that our commitment to cost effectiveness, regulatory rigor and customer service will be a welcome option for peptide researchers and manufacturers," noted Sucheth R. Davuluri, chief executive officer at Neuland Labs.

More information on Neuland's peptide synthesis capabilities is available at Booth #37 at the 22nd American Peptide Symposium, which will be held June 25-30, 2011 at the Sheraton Hotel and Marina in San Diego, California. 

About the American Peptide Society SymposiumEstablished in 1968 by the American Peptide Society, this biannual Symposium assembles national and international peptide scholars, researchers, educators and students together with corporate exhibitors and sponsors. The Symposium brings together investigators of varying backgrounds, with the goal of stimulating discussion, and catalyzing multidisciplinary collaborations in order to push the frontiers of peptide science.  For more information, visit http://www.aps2011.org/

About Neuland Laboratories, Ltd.

For over 25 years Neuland Labs has been at the forefront of supporting drug development through its consulting services and its cGMP contract and API manufacturing.  The company is committed to research, supporting a state-of-the-art R&D operation.  Neuland Labs is listed on India's National Stock Exchange under the symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558.  For more information, visit http://www.NeulandLabs.com Contacts:Neuland Laboratories Limited

US-Neuland Laboratories Inc.

US MediaRavikant Tadinada  

Thomas Speace

BioCom Partners/Brandwidth Solutions+91 9885681385

President & CEO

Barbara LindheimRavikantTadinada@neulandlabs.com

(949) 218-1768

(212) 918-4650TSpeace@neulandlabs.com

blindheim@biocompartners.com
'/>"/>

SOURCE Neuland Laboratories Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Reports Financial Results for Fiscal Year 2011
2. Transgenomic, Inc. Launches Best-in-Class Next-Generation Sequencing Test for Nuclear Mitochondrial Disorders at the 2011 United Mitochondrial Disease Foundation Meeting
3. Multiple Sclerosis Association of America Launches Mobile Phone App for the Multiple Sclerosis Community
4. Ethicon Endo-Surgery Launches ENSEAL® G2 Super Jaw
5. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
6. Vinomis Laboratories Launches Vindurance Challenge to Substantiate Claims of Enhanced Physical Endurance with Use of Resveratrol and Quercetin
7. MedeAnalytics Launches Value-Based Purchasing Resource Center
8. The Institute for Specialized Medicine Launches GLUTEN-FREE REMEDIES, a New Line of Gluten-free Food Supplements and Herbs.
9. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
10. Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
11. Mylan Launches Generic Version of Roxicodone® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... 2017 Research and Markets has announced the ... to their offering. ... arthroscopy devices market to grow at a CAGR of 6.35% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)... Research and Markets has announced the ... Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" report ... ... as well as growth in the number of unit shipments ... market participants that design and manufacture molecular imaging equipment. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... Lake Park Dental is now accepting new patients with crooked ... FL. With the help of this highly-effective, yet convenient system, patients can straighten their ... and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
Breaking Medicine News(10 mins):